Drittlinientherapie mit Gefitinib beim nicht-kleinzelligen Bronchialkarzinom

Zusammenfassung

Mit dem EGFR Tyrosin-Kinase Inhibitor Gefitinib (Iressa™) steht ein neues Therapieprinzip für die Behandlung des nicht-kleinzelligen Bronchialkarzinoms zur Verfügung. Neueste Forschungsarbeiten tragen zu einem besseren Verständnis der Grundlagen der molekularen, zielgerichteten Therapie (Molecular Targeted Therapy, MTT) bei und erlauben es, die bisher vorliegenden Ergebnisse zur klinischen Aktivität von Gefitinib neu zu interpretieren und erstmalig prädiktiv Anhaltspunkte für geeignete Patienten-Subgruppen bei der Therapieentscheidung zu selektionieren.

In der vorliegenden Arbeit werden drei Kasuistiken vorgestellt, an denen aufgezeigt wird, dass vor dem Hintergrund neuer Ergebnisse der translationellen Forschung mit Gefitinib eine wirksame, neue Substanz für die Behandlung chemotherapie-resistenter nicht-kleinzelliger Bronchialkarzinome zur Verfügung steht.

Abstract

The EGFR-inhibition via tyrosine-kinase-inhibitor gefitinib (Iressa™) constitutes a new way to treat non-small-cell lung cancer. Recent research results enable us to better understand the basics of molecular targeted therapy (MTT). These results are helpful to re-interpret the clinical results obtained so far for gefitinib and to consider for the first time in a predictive manner factors for the selection of patients suitable for therapy.

Three case reports are presented in this paper which illustrate that - with view to the results from translational research - the use of gefitinib offers an efficient new therapeutic modality for the treatment of chemotherapy-resistant non-small-cell lung cancer.

Literatur

• 1 Grünwald W, Hidalgo M. Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment.  J Natl Canc Inst. 2003;  95 851-867
• 2 Janmaat M L, Giaccone G. Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.  The Oncologist. 2003;  8 576-586
• 3 Meert A P, Martin B, Delmotte P. et al . The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis.  Eur Respir J. 2002;  4 975-981
• 4 Salomon D, Brandt R, Ciardello F. et al . Epidermal Growth Factor-Related Peptides and their Receptors in Human Malignancies.  Crit Rev Oncol Hematol. 1995;  19 183-232
• 5 Cohen M H, Williams G A, Sridhara R. et al . United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD 1839; Iressa) tablets.  Clin Cancer Res. 2004;  15 1212-1218
• 6 Fukuoka M, Yano S, Giaccone G. et al . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.  J Clin Oncol. 2003;  21 2237-2246
• 7 Kris M G, Natale R B, Herbst R S. et al . Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomised trial.  JAMA. 2003;  290 149-158
• 8 Shepherd F A, Pereira J, Ciuleanu T E. et al . A randomized placebo-controlled trial of Erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1^st line or 2^nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial.  Proc ASCO. 2004;  23 Abst. 7022-7022
• 9 Giaccone G, Herbst R S, Manegold C. et al . Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1.  J Clin Oncol. 2004;  22 777-784
• 10 Herbst R S, Giaccone G, Schiller J H. et al . Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A Phase III Trial: INTACT 2.  J Clin Oncol. 2004;  22 785-794
• 11 Gatzemeier U, Pluzanska A, Szeczesna E. et al . Results of a Phase III Trial of Erlotinib (OSI-774) combined with Cisplatin and Gemcitabine Chemotherapy in advanced non-small-cell lung cancer (NSCLC).  Proc Am Soc Clin Oncol. 2004;  23 Abst. 7010-7010
• 12 Herbst R S, Prager D, Hermann R. et al . TRIBUTE - A phase III trial of erlotinib (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC).  Proc Am Soc Clin Oncol. 2004;  23 Abst. 7011-7011
• 13 Ciardello F, Caputo R, Bianco R. et al . Antitumor Effect and Potentiation of Cytotoxic drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-Selective Tyrosine Kinase Inhibitor.  Clin Cancer Res. 2000;  6 2053-2063
• 14 Baselga J. Combining the Anti-EGFR Agent Gefitinib with Chemotherapy in Non-Small-Cell Lung Cancer: How Do We Go From INTACT to Impact?.  J Clin Oncol. 2004;  22 759-761
• 15 Moscatello D K, Holgado-Madruga M, Emlet D R. et al . Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor.  J Biol Chem. 1998;  273 200-206
• 16 Lynch T J, Bell D W, Sordella R. et al . Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib.  N Engl J Med. 2004;  350 2129-2139
• 17 Paez J G, Jänne P A, Lee G C. et al . EGFR Mutations in Lung Cancer. Correlation with Clinical Response to Gefitinib Therapy.  Science. 2004;  304 1497-1500
• 18 Sordella R, Bell D W, Haber D A. et al . Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways.  Science. 2004;  305 1163-1167
• 19 Wittekind C, Wagner G. TNM-Klassifikation maligner Tumoren, 5. Auflage. Berlin Heidelberg: Springer 1997: 91
• 20 Miller V A, Kris M G, Shah N. et al . Bronchioalveolar Pathologic Subtype and Smoking Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer.  J Clin Oncol. 2004;  22 1103-1109
• 21 Pao W, Miller V, Zakowski M. et al . EGF receptor gene mutations are common in lung cancers from „never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib.  Proc Natl Acad Sci. 2004;  101 13 306-13 311